Dostarlimab-gxly (Jemperli)
Dostarlimab-gxly (Jemperli) is a programmed death receptor-1 (PD-1)–blocking antibody or immune checkpoint inhibitor.
This drug is indicated for use in endometrial cancer with several conditions.
Provider Resource
- About Us
- Resources by Drug Therapy
- Drugs by Tumor Type
- Immunotherapy Types for Drug Therapy
- Avelumab
- Cemiplimab
- Dostarlimab-gxly
- Durvalumab
- Epcoritamab-bysp
- Idecabtagene Vicleucel
- Ipilimumab
- Ipilimumab/nivolumab
- Nivolumab
- Pembrolizumab
- Relatlimab/nivolumab
- Talimogene laherparepvec; T-VEC
- Talquetamab-tgvs
- Tarlatamab-dlle
- Tebentafusp-tebn
- Tisotumab vedotin-tftv
- Provider Resources
- Resources for Your Patients
- International Resources
- About Us
- Resources by Drug Therapy
- Drugs by Tumor Type
- Immunotherapy Types for Drug Therapy
- Avelumab
- Cemiplimab
- Dostarlimab-gxly
- Durvalumab
- Epcoritamab-bysp
- Idecabtagene Vicleucel
- Ipilimumab
- Ipilimumab/nivolumab
- Nivolumab
- Pembrolizumab
- Relatlimab/nivolumab
- Talimogene laherparepvec; T-VEC
- Talquetamab-tgvs
- Tarlatamab-dlle
- Tebentafusp-tebn
- Tisotumab vedotin-tftv
- Provider Resources
- Resources for Your Patients
- International Resources
MENU
- About Us
- Resources by Drug Therapy
- Drugs by Tumor Type
- Immunotherapy Types for Drug Therapy
- Avelumab
- Cemiplimab
- Dostarlimab-gxly
- Durvalumab
- Epcoritamab-bysp
- Idecabtagene Vicleucel
- Ipilimumab
- Ipilimumab/nivolumab
- Nivolumab
- Pembrolizumab
- Relatlimab/nivolumab
- Talimogene laherparepvec; T-VEC
- Talquetamab-tgvs
- Tarlatamab-dlle
- Tebentafusp-tebn
- Tisotumab vedotin-tftv
- Provider Resources
- Resources for Your Patients
- International Resources